We look forward to this year’s World Vaccine Congress in Amsterdam. With the conference in its 25th year, and the event continuing to grow in size, we believe this to be a great place to connect, talk to and meet with new and old colleagues and contemporaries.
Please do visit us at booth 226 and chat with the team present. Not only will the team be present at the booth, but our Chief Scientific Officer, Andrew Catchpole will be presenting in the respiratory track on October 15 at 11:30 titled “High infection rates achieved with the worlds’ first RSV B challenge model; a key component of our RSV-hMPV-PIV combination vaccine efficacy testing platform”.
Presented by Andrew Catchpole, Chief Scientific Officer at hVIVO
Date: October 15
Time: 11:30
Track: Respiratory
At hVIVO, we are a full-service early-phase contract research organisation (CRO) offering end-to-end drug development services from preclinical consultancy through to Phase III clinical trials. Our team brings together strategic insight and operational expertise to deliver a variety of clinical study types, including first-in-human and human challenge trials.
HVIVO, the experts in human challenge trials.
With 13+ fully characterised challenge study models, conducted 80+ studies with 5000+ subjects inoculated hVIVO has unparalleled experience in human challenge trials.
hLAB, our specialist infectious disease laboratory provides specialist expertise in virology, immunology, and molecular biology to support the development of innovative vaccines and therapeutics. Operating within state-of-the-art Biosafety Level 2 and 3 facilities, we deliver high-quality sample analysis and data outputs that empower our clients to achieve proof of concept or drive breakthrough discoveries in the pathology and treatment of diseases with significant unmet medical needs.
Our capabilities span assay development, transfer, and optimisation across immunology, molecular, and cell-based platforms, with extensive options for sample matrix and stability testing. Every assay is validated in line with FDA, EMA, and ICH guidelines, ensuring the highest scientific and regulatory standards. As part of hVIVO, hLAB plays a critical role in our end-to-end early clinical development services, helping a global network of biopharma partners accelerate innovation.
At hVIVO we also offer our sites as a service. All our sites have integrated laboratory or laboratory-processing facilities, including our cutting edge 50-bed quarantine facility in London, with hLAB, our specialist virology and immunology laboratory, on site. Together, our clinical trial sites provide access to a huge participant populations with the capacity to screen over 1000 participants a week.
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
